Study Design for an Open-Label, Efficacy-Assessor-Blinded, Phase 3 Study (START UP) to Compare the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Introduction & Objectives While phase 3 studies established the safety and efficacy of upadacitinib (UPA), an oral JAK inhibitor, for treatment of atopic dermatitis (AD) in adults and adolescents,1-3 it is important to evaluate its safety, efficacy, and optimal dosing in the younger pediatric population. START UP is an...